



Attorney Docket No. ATTE-002/02US

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 30, 2004.

By: Cathi L.G. Thoorsell
Cathi L.G. Thoorsell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Amy L. ALLAN *et al.*

Serial No.: 10/723,144

Examiner: Not yet assigned

Confirmation No.: 9257

Art Unit: 1641

Filed: November 25, 2003

For: **PEPTIDES WHICH INHIBIT ANGIOGENESIS, CELL MIGRATION,
CELL INVASION AND CELL PROLIFERATION, COMPOSITIONS AND
USES THEREOF**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08A for the above-identified patent application. In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required. A return receipt postcard is also enclosed.


The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 03-3117.

Dated: March 30, 2004

Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000 Fax: (650) 857-0663
672763 v1/PA

Respectfully submitted,
COOLEY GODWARD LLP

By: Sunil K. Singh
Sunil K. Singh
Reg. No. 45,298



Attorney Docket No. ATTE-002/02US

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 30, 2004.

By:

Cathi L.G. Thoorsell
Cathi L.G. Thoorsell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Amy L. ALLAN *et al.*

Serial No.: 10/723,144

Examiner: Not yet assigned

Confirmation No.: 9257

Art Unit: 1641

Filed: November 25, 2003

For: **PEPTIDES WHICH INHIBIT ANGIOGENESIS, CELL MIGRATION,
CELL INVASION AND CELL PROLIFERATION, COMPOSITIONS AND
USES THEREOF**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98. Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed. This Information Disclosure Statement is filed before the mailing date of a first office action on the merits.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Dated: March 30, 2004


Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000 Fax: (650) 857-0663
672761 v1/PA

Respectfully submitted,
COOLEY GODWARD LLP

By:

Sunil K. Singh
Sunil K. Singh
Reg. No. 45,298

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

| | | | | | |
|---|---|--------------------------|-------------------|------------------------|---------------|
| Substitute for form 1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/723,144 | | |
| | | Filing Date | November 25, 2003 | | |
| | | First Named Inventor | Amy L. ALLAN | | |
| | | Group Art Unit | 1641 | | |
| | | Examiner Name | Not yet assigned | | |
| Sheet | 1 | of | 5 | Attorney Docket Number | ATTE-002/02US |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|----------------------|--------------------------------------|---|--|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Number | Kind Code ² (if known) | | |
| | P1 | 6,472,369 | | Livant | 10-29-2002 |
| | P2 | 6,001,965 | | Livant | 12-14-1999 |
| | P3 | 5,994,309 | | Mazar <i>et al.</i> | 07-25-1997 |
| | P4 | 5,970,974 | | Van der Linden <i>et al.</i> | 10-26-1999 |
| | P5 | 5,954,047 | | Amer <i>et al.</i> | 09-21-1999 |
| | P6 | 5,950,619 | | van der Linden <i>et al.</i> | 09-10-1997 |
| | P7 | 5,698,155 | | Grosswald <i>et al.</i> | 12-16-1997 |
| | P8 | 5,639,725 | | O'Reilly <i>et al.</i> | 06-17-1997 |
| | P9 | 5,627,286 | | Ramalingam <i>et al.</i> | 05-06-1997 |
| | P10 | 5,618,513 | | Srinivasan | 04-08-1997 |
| | P11 | 5,567,408 | | Zamora | 10-22-1996 |
| | P12 | 5,561,220 | | Dean | 10-01-1996 |
| | P13 | 5,556,611 | | Biesalski | 09-17-1996 |
| | P14 | 5,443,816 | | Zamura <i>et al.</i> | 08-22-1995 |
| | P15 | 5,112,598 | | Biesalski | 05-12-1992 |
| | P16 | 4,765,539 | | Noakes <i>et al.</i> | 08-23-1988 |
| | P17 | 4,683,202 | | Mullis | 07-28-1987 |
| | P18 | 3,916,899 | | Theeuwes <i>et al.</i> | 11-04-1975 |
| | P19 | 3,845,770 | | Theeuwes <i>et al.</i> | 11-05-1974 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | |
| | F1 | | | | | |
| | F2 | | | | | |
| | F3 | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.


³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

| | | | | | |
|---|---|----|--------------------------|------------------------|---------------|
| Substitute for form PTA-49B/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/723,144 | |
| | | | Filing Date | November 25, 2003 | |
| | | | First Named Inventor | Amy L. ALLAN | |
| | | | Group Art Unit | 1614 | |
| | | | Examiner Name | Not yet assigned | |
| Sheet | 2 | of | 5 | Attorney Docket Number | ATTE-002/02US |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | | |
|---|-----------------------|---|----------------|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | D1 | ADELMAN <i>et al.</i> , "In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone," <i>DNA</i> (1983), 2:183-193. | | |
| | D2 | ALDERMAN, "A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms," <i>Int. J. Pharm. Tech. & Prod. Mfr.</i> (1984), 5(3) 1-9. | | |
| | D3 | ALMQUIST <i>et al.</i> , "Synthesis and Biological Activity of a Ketomethylene Analogue of a Tripeptide Inhibitor of Angiotensin Converting Enzyme," <i>J. Med. Chem.</i> (1980), 23:1392 | | |
| | D4 | BALDARI <i>et al.</i> , "A Novel Leader Peptide Which Allows Efficient Secretion of a Fragment of Human Interleukin 1 β in <i>Saccharomyces cerevisiae</i> ," <i>EMBO J.</i> (1987), 6:229-234 | | |
| | D5 | BAMBA <i>et al.</i> , "Release Mechanisms in Gelforming Sustained Release Preparations," <i>Int. J. Pharm.</i> (1979), 2:307-315 | | |
| | D6 | BEAUCAGE <i>et al.</i> , "Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis," <i>Tetrahedron Lett.</i> (1981), 22:1859 | | |
| | D7 | BENJAMIN <i>et al.</i> , "Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal," <i>J. Clin. Invest.</i> (1999), 103:159-165 | | |
| | D8 | BLOOD <i>et al.</i> , "Tumor Interactions with the Vasculature: Angiogenesis and Tumor Metastasis," <i>Biochim. Biophys. Acta</i> (1990), 1032:89-118 | | |
| | D9 | BORGSTROM <i>et al.</i> , "Neutralizing Anti-Vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors In Vivo," <i>Prostate</i> (1998), 35:1-10 | | |
| | D10 | BROOKS <i>et al.</i> , "Disruption of Angiogenesis by PEX, A Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity," <i>Cell</i> (1998), 92:391-400 | | |
| | D11 | BRUCHEZ <i>et al.</i> , "Semiconductor Nanocrystals as Fluorescent Biological Labels," <i>Science</i> (1998), 281:2013-2016 | | |
| | D12 | CHAMBERS <i>et al.</i> , "Macrophage Colony-stimulating Factor Mediates Invasion of Ovarian Cancer Cells through Urokinase," <i>Canc. Res.</i> (1995), 55:1578-1585 | | |
| | D13 | CHAN <i>et al.</i> , "Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection," <i>Science</i> (1998), 281:2016-2018 | | |
| | D14 | CHOREV <i>et al.</i> , "Partially Modified Retro-Inverso-Enkephalinamides: Topochemical Long-Acting Analogs in vitro and in vivo," <i>Science</i> (1979), 204:1210-1212 | | |
| | D15 | CROWLEY <i>et al.</i> , "Prevention of Metastasis by Inhibition of the Urokinase Receptor," <i>Proc. Natl. Acad. Sci USA</i> (1993), 90:5021-5025 | | |
| | D16 | DURING <i>et al.</i> , "Controlled Release of dopamine from a Polymeric Brain Implant: In Vivo Characterization," <i>Ann. Neurol.</i> (1989) 25:351 | | |
| | D17 | EDGE, "Total Synthesis of a Human Leukocyte Interferon Gene," <i>Nature</i> (1981), 292:756-762 | | |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | D18 | FOLKMAN, "Anti-Angiogenesis: New Concept for Therapy of Solid Tumors," <i>Ann. Surg.</i> (1972), 175:409-416 | |
| | D19 | FOLKMAN, "The Influence of Angiogenesis Research on Management of Patients with Breast Cancer," <i>Breast Cancer Res. Treat.</i> (1995), 36(2):109-118 | |
| | D20 | FOLKMAN, "Angiogenesis Inhibitors Generated by Tumors," <i>Mol. Med.</i> (1995), 1(2):120-122; | |
| | D21 | GIANNIS <i>et al.</i> , "Peptidomimetics in Drug Design," <i>Adv. In Drug Res.</i> (1997), 29:1-78 | |
| | D22 | GLUZMAN, "SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants," <i>Cell</i> (1981), 23:175-182 | |
| | D23 | GOODSON, "Medical Application of Controlled Release" 2:115-138 (1984) | |
| | D24 | GORELIK <i>et al.</i> , "Control of Lung Metastasis Progression in Mice: Role of Growth Kinetics of 3LL Lewis Lung Carcinoma and Host Immune Reactivity," <i>J. Nat'l Canc. Inst.</i> , (1980), 65:1257-1264 | |
| | D25 | GORELIK <i>et al.</i> , "Host's Immune State and Kinetics of Local Tumor Growth Control – Progression of Postoperative Lung Metastasis," <i>Rec. Results Canc. Res.</i> (1980), 75:20-28 | |
| | D26 | HANAHAN <i>et al.</i> , "Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis," <i>Cell</i> (1996), 86(3):353-364 | |
| | D27 | HILGARD <i>et al.</i> , "Oral Anticoagulation in the Treatment of a Spontaneously Metastasising Murine Tumour (3LL)," <i>Br. J. Cancer</i> (1977), 35:78-86 | |
| | D28 | HOLLADAY <i>et al.</i> , "Synthesis of Hydroxyethylene and Ketomethylene Dipeptide Isosteres," <i>Tetrahedron Lett.</i> (1983), 24:4401-4404 | |
| | D29 | HOWARD <i>et al.</i> , "Intracerebral drug delivery in rats with lesion-induced memory deficits," <i>J. Neurosurg.</i> (1989), 71:105-112 | |
| | D30 | HRUBY, "Conformational Restrictions of Biologically Active Peptides Via Amino Acid Side Chain Groups," <i>Life Sci.</i> (1982), 4:189-199 | |
| | D31 | HRUBY, "Conformational and Topographical Considerations in the Design of Biologically Active Peptides," <i>Biopolymers</i> (1993), 33:1073-1082 | |
| | D32 | ISAKOV <i>et al.</i> , "An Immune Response against the Alloantigens of the 3LL Lewis Lung Carcinoma Prevents the Growth of Lung Metastases, but Not of Local Allografts," <i>Invasion Matas.</i> (1982) 2:12-32 | |
| | D33 | JAY, "Chemical Synthesis of a Biologically Active Gene for Human Immune Interferon- γ ," <i>J. Biol. Chem</i> (1984), 259:6311-6317 | |
| | D34 | JENNING-WHITE <i>et al.</i> , "Synthesis of Ketomethylene Analogs of Dipeptides," <i>Tetrahedron Lett.</i> (1982), 23:2533-2534 | |
| | D35 | KAUFMAN <i>et al.</i> , "Translational Efficiency of Polycistronic mRNAs and their Utilization to Express Heterologous Genes in Mammalian cells," <i>EMBO J.</i> , (1987), 6:187-195 | |
| | D36 | KLEINMAN <i>et al.</i> , "Basement Membrane Complexes with Biological Activity," <i>Biochemistry</i> (1986), 25:312-318 | |
| | D37 | KURJAN <i>et al.</i> , "Structure of a Yeast Pheromone Gene (MF α): A Putative α -Factor Precursor Contains Four Tandem Copies of Mature α -Factor," <i>Cell</i> , (1982), 30:933-943 | |
| | D38 | LANGER <i>et al.</i> , "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," <i>J. Macromol. Sci. Rev. Macromol Chem.</i> , (1983), 23:61 | |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | D39 | LANGER, "New Methods of Drug Delivery," <i>Science</i> , (1990), 249:1527-1533 | |
| | D40 | LEVY <i>et al.</i> , "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," <i>Science</i> , (1985) 228:190 | |
| | D41 | LUCKLOW <i>et al.</i> , "High Level Expression of Nonfused Foreign Genes with <i>Autographa californica</i> Nuclear Polyhedrosis Virus Expression Vectors," <i>Virology</i> (1989), 170:31-39 | |
| | D42 | MALAVE <i>et al.</i> , "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngeneic Mice," <i>J. Nat'l. Canc. Inst.</i> (1979), 62:83-88 | |
| | D43 | MATTEUCCI <i>et al.</i> , "Synthesis of Deoxyoligonucleotides on a Polymer Support," <i>J. Am. Chem Soc.</i> (1981), 103:3185 | |
| | D44 | MAXAM <i>et al.</i> , "Nucleic Acids," <i>Meth. Enzymol.</i> (1980), 65:499-560 | |
| | D45 | MERRIFIELD, "Solid Phase Peptide Synthesis. I. "The Synthesis of a Tetrapeptide," <i>J. Amer. Chem. Soc.</i> (1963), 85:2149-54 | |
| | D46 | MESSING <i>et al.</i> , "A System for Shotgun DNA Sequencing," <i>Nucleic Acids Res.</i> (1981), 9:309 | |
| | D47 | MILLAUER <i>et al.</i> , "Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types <i>in Vivo</i> ," <i>Cancer Res.</i> (1996), 56:1615-1620 | |
| | D48 | MIN <i>et al.</i> , "Urokinase Receptor Antagonists Inhibit Angiogenesis and Primary Tumor Growth in Syngeneic Mice," <i>Cancer Res.</i> (1996), 56:2428-2433 | |
| | D49 | MOORE <i>et al.</i> , "Design and Pharmacology of Peptide Mimetics," <i>Adv. In Pharmacol.</i> (1995), 33:91-141 | |
| | D50 | NAMBAIR <i>et al.</i> , "Total Synthesis and Cloning of a Gene Coding for the Ribonuclease S Protein," <i>Science</i> (1984), 223:1299-1301 | |
| | D51 | NGUYEN <i>et al.</i> , "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane," <i>Microvascular Res.</i> (1994), 47:31-40 | |
| | D52 | ODEDRA <i>et al.</i> , "Low Molecular Weight Angiogenesis Factors," <i>Pharmac. Ther.</i> (1991), 49:111-124 | |
| | D53 | OLSON <i>et al.</i> , "Concepts and Progress in the Development of Peptide Mimetics," <i>J. Med. Chem.</i> (1993), 36:3039 | |
| | D54 | O'REILLY <i>et al.</i> , "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <i>Cell</i> (1997), 88:277-285 | |
| | D55 | O'REILLY <i>et al.</i> , "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <i>Cell</i> (1994), 79:315-328 | |
| | D56 | PARISH <i>et al.</i> , (1992), "A Basement-Membrane Permeability Assay Which Correlates With The Metastatic Potential of Tumour Cells," <i>Int. J. Cancer</i> 52:378-383 | |
| | D57 | PASSANITI <i>et al.</i> , "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstructed Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Lab Invest.</i> (1992), 67:519-528 | |
| | D58 | RABBANI <i>et al.</i> , "Prevention of Prostate-Cancer Metastasis <i>In Vivo</i> by a Novel Synthetic Inhibitor of Urokinase-Type Plasminogen Activator (uPA)" <i>Int. J. Cancer</i> (1995), 63:840-845 | |
| | D59 | SANGER, "DNA sequencing with chain-terminating inhibitors," <i>Proc. Natl. Acad. Sci. USA</i> (1977), 74:5463-5467 | |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | D60 | SAUDEK <i>et al.</i> , "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," <i>N. Engl. J. Med.</i> (1989), 321:574 | |
| | D61 | SCHNAPER <i>et al.</i> , "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways," <i>J. Cell. Physiol.</i> (1995), 165:107-118 | |
| | D62 | SCHOCKLEY <i>et al.</i> , "Penetration of Tumor Tissue by Antibodies and Other Immunoproteins," <i>Ann. N.Y. Acad. Sci.</i> (1991), 617:367-382 | |
| | D63 | SCHULTZ <i>et al.</i> , "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus," <i>Gene</i> , (1987), 54:113-123 | |
| | D64 | SEFTON, "Implantable Pumps," <i>CRC Crit. Ref. Biomed. Eng.</i> (1987), 14:201 | |
| | D65 | SMITH <i>et al.</i> , "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," <i>Mol. Cell Biol.</i> (1983), 3:2156-2165 | |
| | D66 | SPATOLA, "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins," B. Weinstein, (eds.), <i>Marcel Dekker, New York</i> , (1983) 267-357 | |
| | D67 | SPATOLA <i>et al.</i> , "Structure-Activity Relationships of Enkephalins Containing Serially Replaced Thiomethylene Amide Bond Surrogates," <i>Life Sci.</i> (1986), 38:1243-1249 | |
| | D68 | TALMADGE <i>et al.</i> , "Enhanced Metastatic Potential of Tumor Cells Harvested From Spontaneous Metastases of Heterogeneous Murine Tumors," <i>J. Nat'l. Canc. Inst.</i> (1982), 69:975-980 | |
| | D69 | THAKUR <i>et al.</i> , "Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs," <i>J. Lab. Clin. Med.</i> (1977), 89:217-228 | |
| | D70 | TREAT <i>et al.</i> , "Liposomes in the Therapy of Infectious Diseases and Cancer", <i>Lopez-Berestein and Fidler</i> (eds.), <i>Liss, New York</i> , pp. 353-365 (1989) | |
| | D71 | VERMA <i>et al.</i> , "Osmotically Controlled Oral Drug Delivery," <i>Drug Dev. Ind. Pharm.</i> (2000), 26:695-708 | |
| | D72 | VERSCOYLE <i>et al.</i> , "Pharmacokinetics of Isotretinoin (ISO) in Rats following Oral Dosing or Aerosol Inhalation," <i>British J. Cancer</i> (1999), 80 Suppl. 2, 96 | |
| | D73 | VOLPERT <i>et al.</i> , "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats," <i>J. Clin. Invest.</i> (1996), 98:671-679 | |
| | D74 | WILEY <i>et al.</i> , "Peptidomimetics Derived from Natural Products," <i>Med Res. Rev.</i> (1993), 13:327-384 | |
| | D75 | XING <i>et al.</i> , "Overexpression of Urokinase Receptor in Breast Cancer Cells Results In Increased Tumor Invasion, Growth and Metastasis," <i>Int. J. Cancer</i> (1996), 67:423-429 | |
| | D76 | ZOLLER <i>et al.</i> , "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA," <i>Nucleic Acids Res.</i> (1982), 10:6487-6500 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

672602 v1/PA

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.